OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 130 filers reported holding OCULAR THERAPEUTIX INC in Q3 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $296,259 | -35.2% | 94,350 | +6.5% | 0.00% | – |
| Q2 2023 | $457,176 | -7.2% | 88,600 | -5.2% | 0.00% | – |
| Q1 2023 | $492,745 | +87.5% | 93,500 | 0.0% | 0.00% | – |
| Q4 2022 | $262,735 | -26.8% | 93,500 | +8.2% | 0.00% | – |
| Q3 2022 | $359,000 | -2.7% | 86,400 | -5.8% | 0.00% | – |
| Q2 2022 | $369,000 | -14.2% | 91,700 | +5.6% | 0.00% | – |
| Q1 2022 | $430,000 | -28.8% | 86,800 | +0.2% | 0.00% | – |
| Q4 2021 | $604,000 | -30.3% | 86,600 | 0.0% | 0.00% | – |
| Q3 2021 | $866,000 | -29.5% | 86,600 | 0.0% | 0.00% | – |
| Q2 2021 | $1,228,000 | -13.6% | 86,600 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $1,421,000 | -18.7% | 86,600 | +2.6% | 0.00% | 0.0% |
| Q4 2020 | $1,747,000 | +185.5% | 84,400 | +5.0% | 0.00% | – |
| Q3 2020 | $612,000 | -8.7% | 80,400 | 0.0% | 0.00% | – |
| Q2 2020 | $670,000 | +46.3% | 80,400 | -13.2% | 0.00% | – |
| Q1 2020 | $458,000 | +100.0% | 92,600 | +59.9% | 0.00% | – |
| Q4 2019 | $229,000 | +30.1% | 57,900 | 0.0% | 0.00% | – |
| Q3 2019 | $176,000 | -36.0% | 57,900 | -7.4% | 0.00% | – |
| Q2 2019 | $275,000 | +45.5% | 62,500 | +31.0% | 0.00% | – |
| Q1 2019 | $189,000 | -6.9% | 47,700 | -6.7% | 0.00% | – |
| Q4 2018 | $203,000 | -42.3% | 51,100 | 0.0% | 0.00% | – |
| Q3 2018 | $352,000 | +11.0% | 51,100 | +8.7% | 0.00% | – |
| Q2 2018 | $317,000 | +9.7% | 47,000 | +5.9% | 0.00% | – |
| Q1 2018 | $289,000 | +46.0% | 44,400 | 0.0% | 0.00% | – |
| Q4 2017 | $198,000 | -23.3% | 44,400 | +6.5% | 0.00% | – |
| Q3 2017 | $258,000 | -33.3% | 41,700 | 0.0% | 0.00% | – |
| Q2 2017 | $387,000 | +53.0% | 41,700 | +52.7% | 0.00% | – |
| Q1 2017 | $253,000 | +10.5% | 27,300 | 0.0% | 0.00% | – |
| Q4 2016 | $229,000 | +21.8% | 27,300 | 0.0% | 0.00% | – |
| Q3 2016 | $188,000 | +39.3% | 27,300 | 0.0% | 0.00% | – |
| Q2 2016 | $135,000 | +16.4% | 27,300 | +127.5% | 0.00% | – |
| Q1 2016 | $116,000 | -84.8% | 12,000 | -85.2% | 0.00% | -100.0% |
| Q4 2015 | $761,000 | -7.5% | 81,260 | +38.8% | 0.00% | 0.0% |
| Q3 2015 | $823,000 | +226.6% | 58,544 | +387.9% | 0.00% | – |
| Q2 2015 | $252,000 | +36.2% | 12,000 | +172.7% | 0.00% | – |
| Q1 2015 | $185,000 | – | 4,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,932,607 | $40,643,000 | 15.56% |
| Lamond Capital Partners LLC | 711,533 | $14,964,000 | 15.19% |
| Polaris Venture Management Co. V, L.L.C. | 1,230,009 | $25,867,000 | 11.54% |
| NOTTINGHAM ADVISORS, INC. | 171,985 | $3,617,000 | 0.60% |
| Portolan Capital Management | 122,518 | $2,577,000 | 0.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 160,000 | $3,365,000 | 0.33% |
| Rotella Capital Management, Inc. | 18,461 | $388,000 | 0.32% |
| Monashee Investment Management LLC | 28,834 | $606,000 | 0.29% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 335,498 | $7,056,000 | 0.24% |
| BAILARD, INC. | 55,000 | $1,157,000 | 0.18% |